News & Updates

Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
18 Jul 2022

Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.

Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
18 Jul 2022